D.N. Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 12-12-2024
- Paid Up Capital ₹ 1.46 M
as on 12-12-2024
- Company Age 32 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.36 Cr
as on 12-12-2024
- Revenue 12.72%
(FY 2022)
- Profit 35.98%
(FY 2022)
- Ebitda 33.25%
(FY 2022)
- Net Worth 9.96%
(FY 2022)
- Total Assets 14.07%
(FY 2022)
About D.N. Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.46 M.
The company currently has active open charges totaling ₹2.36 Cr.
Saurabh Sachan, Archana Sachan, and Yogesh Sachan serve as directors at the Company.
- CIN/LLPIN
U24231UP1992PTC014714
- Company No.
014714
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 1992
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Nagar, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at D.N. Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Saurabh Sachan  | Director | 01-Apr-2008 | Current |
| Archana Sachan | Director | 10-Sep-1992 | Current |
| Yogesh Sachan | Director | 10-Sep-1992 | Current |
Financial Performance of D.N. Pharmaceuticals.
D.N. Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 12.72% increase. The company also saw a substantial improvement in profitability, with a 35.98% increase in profit. The company's net worth moved up by a moderate rise of 9.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of D.N. Pharmaceuticals?
In 2022, D.N. Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dinanath Infraheights Private LimitedActive 8 years 11 monthsSaurabh Sachan, Archana Sachan and 1 more are mutual person
- Indo Spice County Private LimitedActive 3 years 5 months
Saurabh Sachan and Yogesh Sachan are mutual person
- Yards Master Infratech Private LimitedActive 4 years 3 months
Saurabh Sachan, Archana Sachan and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 27 Dec 2023 | ₹2.00 Cr | Open |
Idbi Bank Limited Creation Date: 03 Jan 2018 | ₹1.00 M | Open |
Punjab National Bank Creation Date: 15 Apr 2002 | ₹0.40 M | Open |
How Many Employees Work at D.N. Pharmaceuticals?
Unlock and access historical data on people associated with D.N. Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D.N. Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D.N. Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
